Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
University of Florida
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
Emory University
Eastern Cooperative Oncology Group
EMD Serono
Essen Biotech
University of Alabama at Birmingham
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Eli Lilly and Company
Var2 Pharmaceuticals
Hoffmann-La Roche
Mayo Clinic
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
Turning Point Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Hadassah Medical Organization
Fudan University
Nationwide Children's Hospital
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited
PharmaMar
Instituto do Cancer do Estado de São Paulo
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Institut du Cancer de Montpellier - Val d'Aurelle
City of Hope Medical Center
University of South Florida
Stanford University
Cedars-Sinai Medical Center
Bambino Gesù Hospital and Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)